Sling: advancing an oral alternative to Tepezza for thyroid eye

The outsized commercial performance of Tepezza inspired Sling’s founders to repurpose a cancer therapy from Astellas and form a start-up that will develop it as an oral alternative to that thyroid eye disease drug.

Launched this month, Sling Therapeutics Inc. is the first start-up created by TPG, which is the sole investor in the company’s $35 million series A round via its Rise Fund. The company is advancing IGF1R inhibitor linsitinib under a license from Astellas Pharma Inc. (Tokyo:4503); terms are undisclosed...